Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of EZN-2208 with or without cetuximab in metastatic colorectal cancer
NL-OMON34687Phase 2Active, not recruiting
- Sponsor
- Enzon Pharmaceuticals
- Start
- Feb 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of firtecan pegol, cetuximab and irinotecan in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (3 arms), sponsored by Enzon Pharmaceuticals. Primary endpoints: Overall response rate and Progression-free survival. Started Feb 2010; status: active, not recruiting.
02
Drugs
firtecan pegolcetuximabirinotecan
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON34687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34687.